middle.news

Vectus gets a clearer FDA path for VB0004 lung fibrosis trial

8:37am on Monday 16th of November, 2026 AEDT • Biotechnology
Read Story

Vectus gets a clearer FDA path for VB0004 lung fibrosis trial

8:37am on Monday 16th of November, 2026 AEDT
Key Points
  • Supportive FDA responses on VB0004’s CMC, nonclinical and clinical packages
  • Guidance covers the planned Phase Ib/IIa IPF study
  • IND package being finalised with Cardinal Health Regulatory Sciences
  • Study is planned to commence in Australia
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Vectus Biosystems (ASX:VBS)
OPEN ARTICLE